12th Annual Comprehensive Hematology & Oncology Review Course

Instructions

Wednesday, September 1, 2021, 12:00 AM - Thursday, December 1, 2022, 12:00 AM

AMA PRA Category 1 Credits™ (38.00 hours), Non-Physician (38.00 hours)

METHOD OF PARTICIPATION

To complete this training, access to the internet is required. You must receive a minimum passing score of 80% on the post-test (max. 3 attempts) to receive your CME credit. Each module will have a required pre-test, educational component, and post-test.  If after three (3) attempts you are unsuccessful, you will be ineligible to receive CME credit and MOC for the module. However, content will always be available to you. It is important to know that once you have started the Post-Test (Examination), if you exit the Post-Test without responding to all questions, it will be counted as a failed attempt. 

DATE

Date of Original Release: September 1, 2021

Termination Date: November 30, 2022

Registration will close for this online education on June 30, 2022. Users have until the accreditation term ends on November 30, 2022 to complete the selected module(s).

GRANT ACKNOWLEDGEMENT

The University of Washington School of Medicine gratefully acknowledges receipt of educational grant funds in support of this CME activity from AbbVie.

FACULTY & DISCLOSURES

The following course planners have disclosed the following:

• Andrew Coveler, MD (Course Co-Chair/Planner/Reviewer/Speaker): no relevant financial relationships to disclose
• Ryan Cassaday, MD (Course Co-Chair/Planner/Reviewer/Speaker): Honoraria/Consulting/Teaching, Advisory Committees/Review Panels, and/or Grant/Research Support: Amgen, Kite/Gilead, Merck, Pepromene Bio, Pfizer, Vanda Pharmaceuticals
• David Zhen, MD (Course Reviewer/Speaker): Advisory Committees and/or Review Panels: QUD Therapeutics

University of Washington School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

1. Define the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
2. Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
3. Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
4. Incorporate new therapeutic and diagnostic approaches into clinical practice as appropriate.

The certificate fee for all learners is $25.00 per module. The fee for this course includes access to online materials and transcript of AMA PRA Category 1 Credits™ and MOC.

Enduring Material Content

COPYRIGHT
The content is the property of the University of Washington and is protected by law, including but not limited to copyright and trademark statutes. This content is for educational purposes only and may not be used for commercial gain. The University of Washington reserves the right to revise or withdraw content from use. Redistribution of this content is strictly prohibited. For questions related to content use, please contact the CME office at [email protected].

INSTRUCTIONS

• To access to the content, click the hyperlink below for the education module you want to purchase. Register for the education module, then continue with these instructions. You can also find a PDF of these instructions HERE.
• Navigate to "MyCME" at the top and center of your screen.
• Select "Tests"
• New and/or incomplete tests will display automatically on this page.
• Read the activity information for the module prior to starting your pre-test.
• You must complete the pre-test first in order to access the video.
• After completing the video, you must complete the post-test.
• Upon successful completion of the post-test, you will be asked to complete the evaluation. Your CME certificate will be automatically generated after you submit the evaluation.
• Alternatively, you can access the evaluation at a later time. To access the evaluation at a later time, go to "MyCME" and select "Evaluations & Certificates." Complete the required evaluation. Your certificate can also be located here after the evaluation has been submitted.
• A PDF of the presentation available for download can be found above the pre-test button.

Section I	Thoracic, Head and Neck Oncology
EN2201(1A)	NSCLC - Adjuvant/Locally Advanced by Rafael Santana-Davila, MD
EN2201(2A)	Metastatic Non-Small Cell Lung Cancer by Christina Baik, MD, MPH
EN2201(3A)	Small Cell Lung Cancer by Cristina Merkhofer, MD, MHS
EN2201(4A)	Mesothelioma by Cristina Merkhofer, MD, MHS
EN2201(5A)	Head, Neck & Thyroid Cancer by Cristina Rodriguez, MD
Section II	Breast Oncology
EN2201(1B)	Therapy for Non-Invasive Breast Cancer by Rachel Yung, MD
EN2201(2B)	Adjuvant Therapy for Breast Cancer by William Gwin, MD
EN2201(3B)	Metastatic Breast Cancer by Natasha Hunter, MD
Section III	GI Oncology
EN2201(1C)	Esophageal and Gastric Cancer by Veena Shankaran, MD, MS
EN2201(2C)	Carcinoids/PNET by Kit Wong, MD
EN2201(3C)	Hepatocellular Carcinoma by William P. Harris, MD
EN2201(4C)	Pancreas Cancer by Gabriela Chiorean, MD
EN2201(5C)	Cholangiocarcinoma by David Zhen, MD
EN2201(7C)	Colorectal Cancer - Adjuvant by Stacey Cohen, MD
EN2201(8C)	Colorectal Cancer - Metastatic by Stacey Cohen, MD
EN2201(9C)	Anal Cancer by Andrew Coveler, MD
Section IV	GU Oncology
EN2201(6C)	Renal Cell Carcinoma by Scott Tykodi, MD, PhD
EN2201(1D)	Bladder Cancer by Petros Grivas, MD, PhD
EN2201(2D)	Prostate Cancer by Michael Schweizer, MD
EN2201(3D)	Testicular Cancer by Todd Yezefski, MD, MS
Section V	Other Malignancies: GynOnc, CNS, Sarcoma and Melanoma
EN2201(1E)	Cervical and Endometrial Cancers by Kathryn Pennington, MD
EN2201(2E)	Ovarian Cancer by Renata R. Urban, MD
EN2201(3E)	CNS Cancers by Vyshak Venur, MD
EN2201(4E)	Sarcoma by Michael Wagner, MD
EN2201(5E)	Melanoma by Shailender Bhatia, MD
Section VI	Supportive Care & Associated Specialties
EN2201(1F)	Radiation Oncology - Multi-disciplinary by Jonathan Chen, MD, PhD
EN2201(2F)	Supportive Care by Keith Eaton, MD, PhD
EN2201(3F)	Integrative Medicine by Heather Greenlee, ND, PhD, MPH
EN2201(4F)	Familial Syndromes by Everett Lally, MS, CGC
EN2201(5F)	Infectious Disease Complications by Jim Boonyaratanakornkit, MD, PhD
EN2201(6F)	Cancer Pharmacology I by Zakary Cerminara, PharmD, BCOP
EN2201(7F)	Cancer Pharmacology II by Amy Indorf, PharmD, BCOP
Section VII	Lymphomas
EN2201(1G)	Indolent Non-Hodgkin Lymphoma by Solomon Graf, MD
EN2201(2G)	Aggressive Non-Hodgkin Lymphoma by Stephen Smith, MD
EN2201(3G)	T-Cell Lymphomas by Andrei Shustov, MD
EN2201(4G)	Hodgkin Lymphoma by Ryan Lynch, MD
Section VIII	Leukemia and Myelomas
EN2201(1H)	Acute Myeloid Leukemia by Mary-Beth Percival, MD
EN2201(2H)	Chronic Myeloid Leukemia by Vivian Oehler, MD
EN2201(3H)	CLL, SLL & Hairy Cell Leukemia by Mazyar Shadman, MD, MPH
EN2201(4H)	Acute Lymphoblastic Leukemia by Ryan Cassaday, MD
EN2201(5H)	Multiple Myeloma by Sarah Lee, MD
EN2201(6H)	MGUS and Smoldering Myeloma by Mary Kwok, MD
Section IX	Hematology
EN2201(1i)	Inherited and Acquired Marrow Failure by Sioban Keel, MD
EN2201(2i)	Benign White Cell Disorders by Michael Linenberger, MD
EN2201(3i)	The Myelodysplastic Syndromes by Aaron T. Gerds, MD, MS
EN2201(4i)	Myeleoproliferative Neoplasms by Anna Halpern, MD
EN2201(5i)	Thalassemia and Hemoglobinopathies by Oyebimpe Adesina, MD, MS
EN2201(6i)	Iron Metabolism Disorders and Hemolytic Anemias by Kleber Fertrin MD, PhD
EN2201(7i)	Transfusion Medicine by Jill Johnsen, MD
EN2201(8i)	Consultative Hematology by Nicholas Burkwick, MD
EN2201(9i)	Hematopoietic Stem Cell Transplantation by Rachel Salit, MD
EN2201(10i)	Thrombotic Microangiopathies (TTP/HUS) by Ang Li, MD, MS
EN2201(11i)	Thrombocytopenia by Terry Gernsheimer, MD
EN2201(12i)	Thrombosis & Anticoagulation by David Garcia, MD
EN2201(13i)	Bleeding Disorders by Rebecca Kruse-Jarres, MD, MPH

      

ACCREDITATION WITH COMMENDATION: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

MAINTENANCE OF CERTIFICATION (MOC) CREDITS
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Mitigation of Relevant Financial Relationships

University of Washington School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

No faculty are available for this activity at this time.